Kedrion Biopharma Inc.

Kedrion Biopharma is an international biopharmaceutical company headquartered in Barga, Tuscany, Italy, and a leading player in plasma-derived therapeutics. Founded in 2001, Kedrion collects, fractionates, produces, and distributes plasma-derived medicinal products treating coagulation disorders, neurological disorders, primary and secondary immunodeficiencies, and rare genetic disorders. The company operates 68 plasma collection centers in the US and seven production facilities across five countries, serving over 100 countries globally. With approximately 5,200 employees and a portfolio of 38 plasma-derived products, Kedrion is the fifth-largest plasma therapeutics manufacturer worldwide. The company emphasizes research and development of orphan drugs and novel therapeutic proteins, sustainability initiatives, and contract manufacturing services. Notable recent approvals include QIVIGY® and orphan drug designations for aceruloplasminemia treatments. Kedrion demonstrated 10% revenue growth in 2024.